Education
About Us
Working with TipRanks
Follow Us
Tarsus Pharmaceuticals (TARS)
NASDAQ:TARS
TARS Stock Chart & Stats
$61.99
$0.07(0.13%)
At close: 4:00 PM EST
$61.99
$0.07(0.13%)
Day’s Range― - ―
52-Week Range$38.51 - $85.25
Previous CloseN/A
Volume127.14K
Average Volume (3M)529.61K
Market Cap
$2.70B
Enterprise Value$2.60B
Total Cash (Recent Filing)$401.84M
Total Debt (Recent Filing)$82.51M
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Mar 16, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.30
Shares Outstanding42,449,104
10 Day Avg. Volume478,611
30 Day Avg. Volume529,607
Financial Highlights & Ratios
PEG Ratio0.54
Price to Book (P/B)9.27
Price to Sales (P/S)11.38
P/FCF Ratio-24.61
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue7.11
Enterprise Value/Gross Profit8.00
Enterprise Value/Ebitda-35.84
Forecast
1Y Price Target
$89.33Price Target Upside44.10% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Payer Coverage And Patient AccessBroad payer coverage across commercial plans, Medicare, and Medicaid lowers barriers to access and supports continued prescription growth for the therapy.
Prescriber Adoption And Repeat UseRapid expansion in the number of eye-care professionals prescribing Xdemvy, together with rising rates of repeat prescriptions and weekly prescribers, signals accelerating clinical adoption and durable demand.
Sales MomentumConsistent beats on Xdemvy net sales and consecutive periods of product growth indicate sustained revenue momentum and increasing commercial traction.
Bears Say
Medicare Catastrophic Coverage RiskAn increase in Medicare patients moving into catastrophic coverage could change reimbursement dynamics and increase patient cost exposure, potentially constraining uptake in that population.
Rising Operating ExpensesHigher operating costs driven by variable expenses tied to Xdemvy demand and expanded direct-to-consumer investments may pressure margins and reduce near-term profitability.
Tarsus Pharmaceuticals News
TARS FAQ
What was Tarsus Pharmaceuticals’s price range in the past 12 months?
Tarsus Pharmaceuticals lowest stock price was $38.51 and its highest was $85.25 in the past 12 months.
What is Tarsus Pharmaceuticals’s market cap?
Tarsus Pharmaceuticals’s market cap is $2.70B.
When is Tarsus Pharmaceuticals’s upcoming earnings report date?
Tarsus Pharmaceuticals’s upcoming earnings report date is Mar 16, 2026 which is in 38 days.
How were Tarsus Pharmaceuticals’s earnings last quarter?
Tarsus Pharmaceuticals released its earnings results on Nov 04, 2025. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.349 by $0.049.
Is Tarsus Pharmaceuticals overvalued?
According to Wall Street analysts Tarsus Pharmaceuticals’s price is currently Undervalued.
Does Tarsus Pharmaceuticals pay dividends?
Tarsus Pharmaceuticals does not currently pay dividends.
What is Tarsus Pharmaceuticals’s EPS estimate?
Tarsus Pharmaceuticals’s EPS estimate is -0.07.
How many shares outstanding does Tarsus Pharmaceuticals have?
Tarsus Pharmaceuticals has 42,449,104 shares outstanding.
What happened to Tarsus Pharmaceuticals’s price movement after its last earnings report?
Tarsus Pharmaceuticals reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.349. Following the earnings report the stock price went down -4.615%.
Which hedge fund is a major shareholder of Tarsus Pharmaceuticals?
Currently, no hedge funds are holding shares in TARS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tarsus Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$89.33 (44.10% Upside)
$89.33 (44.10% Upside)
Blogger Sentiment
Bullish
TARS Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 84.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.8%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
16.53%
12-Months-Change
Fundamentals
Return on Equity
-28.35%
Trailing 12-Months
Asset Growth
42.06%
Trailing 12-Months
Company Description
Tarsus Pharmaceuticals
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
TARS Company Deck
TARS Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call conveyed a strong positive outlook with exceptional product launch performance, robust financial results, and promising pipeline developments. However, challenges remain in managing Medicare-related discounts and rising operational costs.View all TARS earnings summariesTARS Stock 12 Month Forecast
Average Price Target
$89.33
▲(44.10% Upside)
Technical Analysis
Denali Therapeutics
―
Arcutis Biotherapeutics
―
Beam Therapeutics
―
Disc Medicine
―
Recursion Pharmaceuticals
―
Ownership Overview
3.15% Insiders
20.36% Mutual Funds
2.75% Other Institutional Investors
61.79% Public Companies and
Individual Investors